GSK says it shared its report with the UK drug regulator the following year – and had told it about the paedophilia case within days.
But this specific language about “deviancy” has never appeared in warnings. Rather, they list the potential for an “increased libido”, “harmful behaviour” and an “altered sexual interest”.
We have also learned that, at the same time GSK was compiling its findings, it was also applying to use Ropinirole for a different condition, RLS. It then also collaborated with a private hospital in the US to see if its drug was effective as a treatment for sexual dysfunction in 2005.
GSK told the BBC that its drug was extensively trialled, continues to be approved by regulators around the world, and that side effects are…